For treating diabetes, it has been considered important that both a post prandial blood glucose level and a fasting blood glucose level are decreased to make them to normal levels. Nateglinide [N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine] is a novel mealtime glucose regulator approved for the treatment of type II diabetes mellitus. Once a day sustained release matrix tablets of nateglinide was prepared by using natural polymers k-carrageenan,lambda carrageenan and locust bean gum. Natural polymers were selected due to their easy availability and cheaper in coast and we can get standard uniformity and combinations of two different gums carrageenan and locust been gum were formulated in different ratios to exploit the rheological ...
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial g...
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial g...
Diabetes mellitus is a metabolic disorder caused by insufficient production of endogenous insulin, w...
The purpose of this research work was to formulate and evaluate the sustained release tablets of Nat...
ABSTRACT In the present research work gastro retentive mucoadhesive floating formulation of Nategli...
The present work was to study the effect of biodegradable and synthetic polymers on sustained releas...
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.jddst.2019.1013...
The aim of present study is to formulate and evaluate extended release matrix tablet of Nateglinide ...
Vildagliptin has a low biological half-life of 90 minutes along with having less bioavailability whi...
  Objective: Nateglinide (NTG) is a potent short-acting biopharmaceutical classification system cl...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
AbstractThe aim of this study was to characterize the provesicle formulation of nateglinide (NTG) to...
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial g...
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial g...
Diabetes mellitus is a metabolic disorder caused by insufficient production of endogenous insulin, w...
The purpose of this research work was to formulate and evaluate the sustained release tablets of Nat...
ABSTRACT In the present research work gastro retentive mucoadhesive floating formulation of Nategli...
The present work was to study the effect of biodegradable and synthetic polymers on sustained releas...
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.jddst.2019.1013...
The aim of present study is to formulate and evaluate extended release matrix tablet of Nateglinide ...
Vildagliptin has a low biological half-life of 90 minutes along with having less bioavailability whi...
  Objective: Nateglinide (NTG) is a potent short-acting biopharmaceutical classification system cl...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateg...
AbstractThe aim of this study was to characterize the provesicle formulation of nateglinide (NTG) to...
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial g...
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial g...
Diabetes mellitus is a metabolic disorder caused by insufficient production of endogenous insulin, w...